Author:
Maximov Philipp Y.,McDaniel Russell E.,Jordan V. Craig
Reference85 articles.
1. Gradishar WJ, Jordan VC (1997) Clinical potential of new antiestrogens. J Clin Oncol 15:840–852
2. Stein S, Zoltick B, Peacock T et al (2001) Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. Am J Clin Oncol 24:283–285
3. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS (2002) Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62:1370–1376
4. Lerner LJ, Holthaus FJ Jr, Thompson CR (1958) A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology 63:295–318
5. Jordan VC, Collins MM, Rowsby L, Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305–316